Anita De Rossi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/686890/publications.pdf

Version: 2024-02-01

272 papers	8,708 citations	38720 50 h-index	71651 76 g-index
274 all docs	274 docs citations	274 times ranked	7233 citing authors

#	Article	IF	Citations
1	The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. Aids, 1995, 9, F7-F11-984.	1.0	270
2	Exposure to Antiretroviral Therapy in Utero or Early Life: the Health of Uninfected Children Born to HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 380-387.	0.9	233
3	Combination antiretroviral therapy and duration of pregnancy. Aids, 2000, 14, 2913-2920.	1.0	228
4	INFANTS BORN TO MOTHERS SEROPOSITIVE FOR HUMAN IMMUNODEFICIENCY VIRUS. Lancet, The, 1987, 329, 1164-1168.	6.3	205
5	Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood, 2008, 111, 5142-5151.	0.6	142
6	Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. Aids, 1999, 13, 1377-1385.	1.0	140
7	Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet, The, 2000, 355, 1331-1332.	6.3	127
8	First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infectious Diseases, The, 2011, 11, 273-283.	4.6	123
9	Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. Aids, 2001, 15, 357-368.	1.0	119
10	Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment. Cancer Letters, 2015, 369, 37-44.	3.2	118
11	Time to Undetectable Viral Load after Highly Active Antiretroviral Therapy Initiation among HIV-Infected Pregnant Women. Clinical Infectious Diseases, 2007, 44, 1647-1656.	2.9	114
12	Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. British Journal of Cancer, 2010, 102, 1300-1305.	2.9	110
13	Antigen detection, virus culture, polymerase chain reaction, and in vitro antibody production in the diagnosis of vertically transmitted HIV-1 infection. Aids, 1991, 5, 15-20.	1.0	106
14	Impact of Human Immunodeficiency Virus Type 1 Subtypes on Virologic Response and Emergence of Drug Resistance among Children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. Journal of Infectious Diseases, 2002, 186, 617-625.	1.9	104
15	Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. European Journal of Cancer, 1999, 35, 1809-1815.	1.3	102
16	Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection.. Journal of Clinical Investigation, 1996, 97, 323-330.	3.9	98
17	Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 2433-2437.	3.3	90
18	Differential response to the cytopathic effects of human T-cell lymphotropic virus type III (HTLV-III) superinfection in T4+ (helper) and T8+ (suppressor) T-cell clones transformed by HTLV-I.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 4297-4301.	3.3	89

#	Article	IF	Citations
19	In young men sperm telomere length is related to sperm number and parental age. Human Reproduction, 2013, 28, 3370-3376.	0.4	89
20	Age and CD4 Count at Initiation of Antiretroviral Therapy in HIV-Infected Children: Effects on Long-term T-Cell Reconstitution. Journal of Infectious Diseases, 2012, 205, 548-556.	1.9	85
21	Relationship Between Tumor and Plasma Levels of hTERT mRNA in Patients with Colorectal Cancer: Implications for Monitoring of Neoplastic Disease. Clinical Cancer Research, 2008, 14, 7444-7451.	3.2	82
22	Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects. Clinical Immunology and Immunopathology, 1988, 46, 342-351.	2.1	79
23	Premature aging and immune senescence in HIV-infected children. Aids, 2016, 30, 1363-1373.	1.0	79
24	Risk factors for mother-to-child transmission of HIV-1. International Journal of Gynecology and Obstetrics, 1992, 39, 357-357.	1.0	77
25	IN-VITRO PRODUCTION OF HIV-SPECIFIC ANTIBODY IN CHILDREN AT RISK OF AIDS. Lancet, The, 1988, 331, 852-854.	6.3	76
26	Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells. Journal of Virology, 1997, 71, 3341-3345.	1.5	76
27	Increased Thymic Output after Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus Type 1â€“Infected Children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. Journal of Infectious Diseases, 2002, 186, 312-320.	1.9	73
28	Dynamics of Epsteinâ€“Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. Aids, 2002, 16, 63-73.	1.0	73
29	CD4 Cell Response to Antiretroviral Therapy in Children with Vertically Acquired HIV Infection: Is It Associated with Age at Initiation?. Journal of Infectious Diseases, 2006, 193, 954-962.	1.9	73
30	Mode of delivery in HIVâ€infected pregnant women and prevention of motherâ€toâ€child transmission: changing practices in Western Europe. HIV Medicine, 2010, 11, 368-378.	1.0	73
31	Detection of virus in vertically exposed HIV-antibody-negative children. Lancet, The, 1996, 347, 213-215.	6.3	72
32	Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. Clinical Cancer Research, 2019, 25, 1828-1837.	3.2	72
33	Use of Zidovudine-Sparing HAART in Pregnant HIV-Infected Women in Europe: 2000â€“2009. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 326-333.	0.9	71
34	Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. Aids, 1995, 9, 427-434.	1.0	70
35	Clonal selection of T lymphocytes infected by cell-free human T-cell leukemia/lymphoma virus type I: Parameters of virus integration and expression. Virology, 1985, 143, 640-645.	1.1	69
36	Vertical transmission of HIV-1. Aids, 1992, 6, 1117-1120.	1.0	67

#	Article	IF	Citations
37	CD8+ T lymphocytes in the lung of acquired immunodeficiency syndrome patients harbor human immunodeficiency virus type 1. Blood, 1995, 85, 2308-2314.	0.6	67
38	Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy. Clinical and Experimental Immunology, 2007, 150, 442-450.	1.1	66
39	Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma Regression After Highly Active Antiretroviral Therapy: Biologic Correlates of Clinical Outcome. Journal of the National Cancer Institute Monographs, 2000, 2000, 44-49.	0.9	65
40	Latent Membrane Protein 1 of Epstein-Barr Virus Activates the hTERT Promoter and Enhances Telomerase Activity in B Lymphocytes. Journal of Virology, 2008, 82, 10175-10187.	1.5	65
41	Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. Aids, 2002, 16, 839-849.	1.0	62
42	Telomere-Specific Reverse Transcriptase (hTERT) and Cell-free RNA in Plasma as Predictors of Pathologic Tumor Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. Annals of Surgical Oncology, 2012, 19, 3089-3096.	0.7	61
43	Replication and tropism of human immunodeficiency virus type 1 as predictors of disease outcome in infants with vertically acquired infection. Journal of Pediatrics, 1993, 123, 929-936.	0.9	60
44	Role of Î²-Defensin-1 Polymorphisms in Mother-to-Child Transmission of HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 13-19.	0.9	59
45	Telomeres, telomerase and colorectal cancer. World Journal of Gastroenterology, 2014, 20, 1940.	1.4	59
46	Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia, 2007, 21, 965-972.	3.3	57
47	Early and Highly Suppressive Antiretroviral Therapy Are Main Factors Associated With Low Viral Reservoir in European Perinatally HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 269-276.	0.9	57
48	Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. Aids, 2007, 21, 947-955.	1.0	56
49	Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. British Journal of Cancer, 2013, 108, 278-284.	2.9	56
50	Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys?. Aids, 2002, 16, 97-104.	1.0	55
51	In Vitro Studies of HIV-1 Infection in Thymic Lymphocytes: A Putative Role of the Thymus in AIDS Pathogenesis. AIDS Research and Human Retroviruses, 1990, 6, 287-298.	0.5	53
52	HTLV-I and HTLV-II infections among HIV-1 seropositive patients in Sao Paulo, Brazil. European Journal of Epidemiology, 1994, 10, 165-171.	2.5	53
53	Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system. Journal of the Neurological Sciences, 1994, 126, 49-53.	0.3	53
54	Epstein-Barr Virus load and immune activation in Human Immunodeficiency Virus type 1-infected patients. Journal of Clinical Virology, 2012, 53, 195-200.	1.6	51

#	Article	IF	Citations
55	Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. British Journal of Haematology, 1999, 106, 662-668.	1.2	50
56	Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications. Cancer and Metastasis Reviews, 2016, 35, 457-474.	2.7	48
57	Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies. Cell Reports, 2021, 34, 108852.	2.9	48
58	Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica, 2012, 97, 56-63.	1.7	47
59	Immune senescence and cancer in elderly patients: Results from an exploratory study. Experimental Gerontology, 2013, 48, 1436-1442.	1.2	47
60	HIV-1 Induces Down-Regulation of bcl-2 Expression and Death by Apoptosis of EBV-Immortalized B Cells: A Model for a Persistent "Self-Limiting" HIV-1 Infection. Virology, 1994, 198, 234-244.	1.1	46
61	Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. Aids, 2001, 15, 1074-1075.	1.0	46
62	Early Therapy in HIV-1-Infected Children: Effect on HIV-1 Dynamics and HIV-1-Specific Immune Response. Antiviral Therapy, 2008, 13, 47-56.	0.6	46
63	Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism. Virology, 1991, 184, 187-196.	1.1	45
64	HIV-1 Infection of the Thymus: Evidence for a Cytopathic and Thymotropic Viral Variantin Vivo. AIDS Research and Human Retroviruses, 1995, 11, 11-19.	0.5	44
65	Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. Aids, 2000, 14, 1721-1729.	1.0	44
66	Longâ€Term Decay of the HIVâ€1 Reservoir in HIVâ€1â€“Infected Children Treated with Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2006, 193, 1718-1727.	1.9	44
67	Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers. Pediatrics, 2021, 148, .	1.0	44
68	Relationship between the V3 loop and the phenotypes of human immunodeficiency virus type 1 (HIV-1) isolates from children perinatally infected with HIV-1. Journal of Virology, 1995, 69, 82-92.	1.5	44
69	Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease. Journal of Virology, 1997, 71, 4694-4706.	1.5	44
70	Human Immunodeficiency Virus Type 1 Modulates Telomerase Activity in Peripheral Blood Lymphocytes. Journal of Infectious Diseases, 2001, 183, 417-424.	1.9	43
71	Effects of CCR5-Î”32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children. Aids, 2003, 17, 1631-1638.	1.0	42
72	Age-Related Standards for Total Lymphocyte, CD4+ and CD8+ T Cell Counts in Children Born in Europe. Pediatric Infectious Disease Journal, 2005, 24, 595-600.	1.1	42

#	Article	IF	Citations
73	Immunological Markers in the Cerebrospinal Fluid of HIVâ€1â€Infected Children. Acta Paediatrica, International Journal of Paediatrics, 1991, 80, 659-666.	0.7	41
74	Regulatory T cells and chronic immune activation in human immunodeficiency virus 1 (HIV-1)-infected children. Clinical and Experimental Immunology, 2011, 164, 373-380.	1.1	40
75	Polymorphisms in the CCR5 Promoter Region Influence Disease Progression in Perinatally Human Immunodeficiency Virus Type 1â€"Infected Children. Journal of Infectious Diseases, 2001, 183, 814-818.	1.9	39
76	Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection. JAMA Network Open, 2022, 5, e2221616.	2.8	39
77	Molecular Profile of Epstein-Barr Virus in Human Immunodeficiency Virus Type 1â€"Related Lymphadenopathies and Lymphomas. Blood, 1997, 90, 313-322.	0.6	38
78	Response to planned treatment interruptions in HIV infection varies across childhood. Aids, 2010, 24, 231-241.	1.0	38
79	IgG Oligoclonal Bands in Sera of HIV-1 Infected Patients Are Mainly Directed Against HIV-1 Determinants. AIDS Research and Human Retroviruses, 1990, 6, 581-586.	0.5	37
80	POLYMERASE CHAIN REACTION AND IN-VITRO ANTIBODY PRODUCTION FOR EARLY DIAGNOSIS OF PAEDIATRIC HIV INFECTION. Lancet, The, 1988, 332, 278.	6.3	36
81	Identification of Human Immunodeficiency Virus Type 1 Glycoprotein gp120/gp41 Interacting Sites by the Idiotypic Mimicry of Two Monoclonal Antibodies. AIDS Research and Human Retroviruses, 1993, 9, 33-39.	0.5	36
82	Toll-like receptor 9 polymorphisms influence mother-to-child transmission of human immunodeficiency virus type 1. Journal of Translational Medicine, 2010, 8, 49.	1.8	36
83	Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells. Cell Death and Disease, 2016, 7, e2562-e2562.	2.7	36
84	Diagnosis of human immunodeficiency virus 1 infection in infants. Pediatric Infectious Disease Journal, 1990, 9, 26-30.	1.1	35
85	Sensitivity of Two Enzyme-linked Immunosorbent Assay Tests in Relation to Western Blot in Detecting Human T-Cell Lymphotropic Virus Types I and II Infection among HIV-1 Infected Patients from SÃ£o Paulo, Brazil. Diagnostic Microbiology and Infectious Disease, 1998, 30, 173-182.	0.8	35
86	Pediatric Human Immunodeficiency Virus infection and cancer in the Highly Active Antiretroviral Treatment (HAART) era. Cancer Letters, 2014, 347, 38-45.	3.2	35
87	Telomere shortening in mucosa surrounding the tumor: Biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 500-507.	0.8	35
88	Infection of Epstein-Barr virus-transformed lymphoblastoid B cells by the human immunodeficiency virus: evidence for a persistent and productive infection leading to B cell phenotypic changes. European Journal of Immunology, 1990, 20, 2041-2049.	1.6	34
89	Perinatal infection by human immunodeficiency virus type 1 (HIVâ€"1): Relationship between proviral copy number in vivo, viral properties in vitro, and clinical outcome. Journal of Medical Virology, 1991, 35, 283-289.	2.5	34
90	Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Frontiers in Microbiology, 2013, 4, 311.	1.5	34

#	Article	IF	Citations
91	Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission. Lancet Infectious Diseases, The, 2015, 15, 1108-1114.	4.6	34
92	hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: Implications for EBV-driven lymphomagenesis. International Journal of Cancer, 2007, 121, 576-587.	2.3	33
93	Single-nucleotide polymorphisms in human Î²-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. Aids, 2008, 22, 1515-1517.	1.0	33
94	Current and Future Antiretroviral Treatment Options in Paediatric HIV Infection. Clinical Drug Investigation, 2008, 28, 375-397.	1.1	32
95	Reliable and versatile immortal muscle cell models from healthy and myotonic dystrophy type 1 primary human myoblasts. Experimental Cell Research, 2016, 342, 39-51.	1.2	32
96	Horizontal Transmission of Human Immunodeficiency Virus Type 1 from Father to Child. AIDS Research and Human Retroviruses, 1998, 14, 1679-1685.	0.5	31
97	Restriction of HIV Type 1 Infection in Macrophages Heterozygous for a Deletion in the CC-Chemokine Receptor 5 Gene. AIDS Research and Human Retroviruses, 1999, 15, 1441-1452.	0.5	31
98	Molecular analysis of a deletion mutant provirus of type I human T-cell lymphotropic virus: evidence for a doubly spliced x-lor mRNA.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 38-42.	3.3	30
99	Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. Aids, 1995, 9, 427-434.	1.0	30
100	Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy. Cancers, 2011, 3, 2176-2194.	1.7	30
101	Telomere/telomerase interplay in virusâ€driven and virusâ€independent lymphomagenesis: pathogenic and clinical implications. Medicinal Research Reviews, 2012, 32, 233-253.	5.0	30
102	Vulvar Carcinoma in a 12-Year-Old Girl With Vertically Acquired Human Immunodeficiency Virus Infection. Pediatrics, 2000, 106, e57-e57.	1.0	30
103	HIV-mediated immunodepression: in vitro inhibition of T-lymphocyte proliferative response by ultraviolet-inactivated virus. Clinical Immunology and Immunopathology, 1988, 46, 37-54.	2.1	29
104	Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 433-438.	0.6	29
105	The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection. PLoS ONE, 2013, 8, e76582.	1.1	29
106	Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death and Disease, 2015, 6, e1774-e1774.	2.7	28
107	Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antiviral Therapy, 2008, 13, 47-55.	0.6	28
108	hTERT Inhibition Triggers Epsteinâ€“Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies. Clinical Cancer Research, 2013, 19, 2036-2047.	3.2	27

#	Article	IF	Citations
109	Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. Aids, 1995, 9, 427-34.	1.0	27
110	CD4 modulation and inhibition of HIV-1 infectivity induced by monosialoganglioside GM1 in vitro. Aids, 1989, 3, 501-508.	1.0	26
111	HIV-1 variability and progression to AIDS: A longitudinal study. Journal of Medical Virology, 1990, 32, 252-256.	2.5	26
112	A new epitope presenting system displays a HIV-1 V3 loop sequence and induces neutralizing antibodies. Vaccine, 1995, 13, 1233-1239.	1.7	26
113	Increasing likelihood of further live births in HIV-infected women in recent years. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 881-888.	1.1	26
114	Sister chromatid exchanges induced in vivo and in vitro by chemical carcinogens in mouse lymphocytes carrying endogenized Moloney leukemia virus. Carcinogenesis, 1983, 4, 33-37.	1.3	25
115	Immunologic abnormalities in angioimmunoblastic lymphadenopathy. Cancer, 1987, 60, 2412-2418.	2.0	25
116	Central Nervous System Involvement in HIV Infection. AIDS Research and Human Retroviruses, 1988, 4, 211-221.	0.5	25
117	Pattern of Antibody Response against the V3 Loop in Children with Vertically Acquired		

#	Article	IF	Citations
127	Insufficient Antiretroviral Therapy in Pregnancy: Missed Opportunities for Prevention of Mother-To-Child Transmission of HIV in Europe. Antiviral Therapy, 2011, 16, 895-903.	0.6	22
128	The EPIICAL project:â€,an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children. Journal of Virus Eradication, 2015, 1, 134-139.	0.3	22
129	HTLV-III and HTLV-I infection in populations at risk in the veneto region of Italy. European Journal of Cancer & Clinical Oncology, 1986, 22, 411-418.	0.9	21
130	Polymorphisms of innate immunity genes influence disease progression in HIV-1-infected children. Aids, 2012, 26, 765-768.	1.0	21
131	Epstein-Barr Virus Load in Children Infected With Human Immunodeficiency Virus Type 1 in Uganda. Journal of Infectious Diseases, 2014, 210, 392-399.	1.9	21
132	Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. Oncotarget, 2015, 6, 18653-18663.	0.8	21
133	Evolution of Antiretroviral Phenotypic and Genotypic Drug Resistance in Antiretroviral-Naive HIV-1-Infected Children Treated with Abacavir/Lamivudine, Zidovudine/Lamivudine or Abacavir/Zidovudine, with or without Nelfinavir (The Penta 5 Trial). Antiviral Therapy, 2002, 7, 293-303.	0.6	21
134	Search for HTLV-I and LAV/HTLV-III antibodies in serum and CSF of multiple sclerosis patients. Acta Neurologica Scandinavica, 1986, 74, 161-164.	1.0	20
135	Primary Lymphoma of the Central Nervous System in Two Children with Acquired Immune Deficiency Syndrome. American Journal of Clinical Pathology, 1990, 94, 722-728.	0.4	20
136	Serological and molecular evidence of infection by human T-cell lymphotropic virus type II in Italian drug addicts by use of synthetic peptides and polymerase chain reaction. European Journal of Cancer & Clinical Oncology, 1991, 27, 835-838.	0.9	20
137	HTLV-I/II Seroprevalence in The Gambia: A Study of Mother-Child Pairs. AIDS Research and Human Retroviruses, 1994, 10, 617-620.	0.5	20
138	HIV load in highly purified CD8+ T cells retrieved from pulmonary and blood compartments. Journal of Leukocyte Biology, 1998, 64, 298-301.	1.5	20
139	A search for human herpesvirus 8(HHV-8) in HIV-1 infected mothers and their infants does not suggest vertical transmission of HHV-8. International Journal of Cancer, 2000, 85, 296-297.	2.3	20
140	Different Distribution of HIV Type 1 Genetic Variants in European Patients with Distinct Risk Practices. AIDS Research and Human Retroviruses, 2000, 16, 299-304.	0.5	20
141	The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. British Journal of Cancer, 2018, 118, 878-886.	2.9	20
142	The CARMA Study: Early Infant Antiretroviral Therapyâ€"Timing Impacts on Total HIV-1 DNA Quantitation 12 Years Later. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 295-301.	0.6	20
143	Recurrent oral condylomata acuminata and hairy leukoplakia: an early sign of myelodysplastic syndrome in an HIV-seronegative patient. Journal of Oral Pathology and Medicine, 1991, 20, 398-402.	1.4	19
144	Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Acta Paediatrica, International Journal of Paediatrics, 1999, 88, 228-232.	0.7	19

#	Article	IF	Citations
145	Virological and immunological features of SARSâ€COVâ€2 infected children with distinct symptomatology. Pediatric Allergy and Immunology, 2021, 32, 1833-1842.	1.1	19
146	Cerebrospinal fluid lymphocytes from HIV-infected patients synthesize HIV-specific antibody in vitro. Journal of Neuroimmunology, 1988, 18, 181-186.	1.1	18
147	Free light chains of immunoglobulins in the cerebrospinal fluid of human immunodeficiency virus type 1-infected patients. Journal of Neuroimmunology, 1990, 26, 229-238.	1.1	18
148	Trends of HTLV-I and HIV infections in drug addicts. European Journal of Cancer & Clinical Oncology, 1988, 24, 279-280.	0.9	17
149	Viral phenotype in motherâ€toâ€child HIVâ€1 transmission and disease progression of vertically acquired HIVâ€1 infection. Acta Paediatrica, International Journal of Paediatrics, 1997, 86, 22-28.	0.7	17
150	Antiretroviral Therapy for Prevention of Mother-to-Child HIV Transmission. Clinical Drug Investigation, 2006, 26, 611-627.	1.1	17
151	Within and between race differences in lymphocyte, CD4+, CD8+ and neutrophil levels in HIV-uninfected children with or without HIV exposure in Europe and Uganda. Annals of Tropical Paediatrics, 2006, 26, 169-179.	1.0	17
152	Biphasic decay of cell-associated HIV-1 DNA in HIV-1-infected children on antiretroviral therapy. Aids, 2002, 16, 1961-1963.	1.0	17
153	Hospitalization of children born to human immunodeficiency virus-infected women in Europe. Pediatric Infectious Disease Journal, 1997, 16, 1151-1156.	1.1	17
154	The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children. Journal of Virus Eradication, 2015, 1, 134-139.	0.3	17
155	Vertical transmission of HIV-1: lack of detectable virus in peripheral blood cells of infected children at birth. Aids, 1992, 6, 1117-20.	1.0	17
156	Anti-HIV Activity and Conformational Studies of Peptides Derived from the C-Terminal Sequence of SDF-1. Journal of Medicinal Chemistry, 2004, 47, 3058-3064.	2.9	16
157	Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverseâ€Transcriptase Inhibitors in HIV Type 1â€“Infected Children. Clinical Infectious Diseases, 2008, 46, 1601-1608.	2.9	16
158	Molecular Profile of Epstein-Barr Virus in Human Immunodeficiency Virus Type 1â€“Related Lymphadenopathies and Lymphomas. Blood, 1997, 90, 313-322.	0.6	16
159	The changing epidemiology of acute type B hepatitis: Results of an 11-year prospective study in padua (Northern Italy). Infection, 1989, 17, 364-368.	2.3	15
160	Minimal Sequence Requirements for Synthetic Peptides Derived from the V3 Loop of the Human Immunodeficiency Virus Type 1 (HIV-1) to Enhance HIV-1 Binding to Cells and Infection. Virology, 1995, 206, 807-816.	1.1	15
161	TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 381-389.	1.2	15
162	TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients. Cancers, 2020, 12, 946.	1.7	15

#	Article	IF	Citations
163	Immune senescence and immune activation in elderly colorectal cancer patients. Aging, 2019, 11, 3864-3875.	1.4	15
164	Cross-talk between virus and host innate immunity in pediatric HIV-1 infection and disease progression. New Microbiologica, 2012, 35, 249-57.	0.1	15
165	LAV/HTLV-III and HTLV-I Antibodies in Hemodialysis Patients. Nephron, 1986, 44, 377-378.	0.9	14
166	Immortalization of human T lymphocytes by HTLV-I: Phenotypic characteristics of target cells and kinetics of virus integration and expression. Leukemia Research, 1986, 10, 1109-1120.	0.4	14
167	A search for human herpesvirus 8 (HHV-8) in HIV-1 infected mothers and their infants does not suggest vertical transmission of HHV-8. International Journal of Cancer, 2000, 85, 296-297.	2.3	14
168	Genotypic and Phenotypic Correlates of the HIV Type 1envGene Evolution in Infected Children with Discordant Response to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 1306-1313.	0.5	14
169	Relationship between Non-Hodgkinâ€™s lymphoma and blood levels of Epstein-Barr Virus in children in north-western Tanzania: a case control study. BMC Pediatrics, 2013, 13, 4.	0.7	14
170	Quantitative HIV-1 proviral DNA detection: a multicentre analysis. New Microbiologica, 2010, 33, 293-302.	0.1	14
171	Antiretroviral activity of furocoumarins plus UVA light detected by a replication-defective retrovirus. Journal of Photochemistry and Photobiology B: Biology, 1994, 26, 241-247.	1.7	13
172	Analysis of the CC chemokine receptor 5 m303 mutation in infants born to HIV-1-seropositive mothers. Aids, 1999, 13, 871.	1.0	13
173	The Role of Genetic Variants of Stromal Cell-Derived Factor 1 in Pediatric HIV-1 Infection and Disease Progression. PLoS ONE, 2012, 7, e44460.	1.1	13
174	Role of miR-15a/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia. Haematologica, 2017, 102, e253-e256.	1.7	13
175	Immune activation, immune senescence and levels of Epstein Barr Virus in kidney transplant patients: Impact of mTOR inhibitors. Cancer Letters, 2020, 469, 323-331.	3.2	13
176	T cell immune discriminants of HIV reservoir size in a pediatric cohort of perinatally infected individuals. PLoS Pathogens, 2021, 17, e1009533.	2.1	13
177	Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood, 1997, 90, 313-22.	0.6	13
178	Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma. Neuro-Oncology, 2018, 20, 1142-1143.	0.6	12
179	Genetic Variants of the TERT Gene, Telomere Length, and Circulating TERT as Prognostic Markers in Rectal Cancer Patients. Cancers, 2020, 12, 3115.	1.7	12
180	A Randomized Controlled Trial of Genotypic HIV Drug Resistance Testing in HIV-1-Infected Children: The Pera (Penta 8) Trial. Antiviral Therapy, 2006, 11, 857-868.	0.6	12

#	Article	IF	Citations
181	Viral Load Detection Using Dried Blood Spots in a Cohort of HIV-1-Infected Children in Uganda: Correlations with Clinical and Immunological Criteria for Treatment Failure. Journal of Clinical Microbiology, 2014, 52, 2665-2667.	1.8	11
182	Epstein-Barr virus and telomerase: from cell immortalization to therapy. Infectious Agents and Cancer, 2014, 9, 8.	1.2	11
183	Biological Aging and Immune Senescence in Children with Perinatally Acquired HIV. Journal of Immunology Research, 2020, 2020, 1-15.	0.9	11
184	Reciprocal activation of human T-lymphotropic viruses in HTLV-I-transformed cells superinfected with HIV-1. Journal of Acquired Immune Deficiency Syndromes, 1991, 4, 380-5.	1.0	11
185	Lav/HTLV-III Neutralizing Antibodies in the Sera of Patients with Aids, Lymphadenopathy Syndrome and Asymptomatic Seropositive Individuals. Tumori, 1986, 72, 219-224.	0.6	10
186	Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIVâ€infected infants and toddlers. British Journal of Clinical Pharmacology, 2012, 73, 641-650.	1.1	10
187	Protection from spontaneous lymphoma development in SJL/J(v+) mice neonatally injected with dualtropic SJL-151 virus.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 2775-2779.	3.3	9
188	Dominance of a single Epstein-Barr virus strain in SCID-mouse tumors induced by injection of peripheral blood mononuclear cells from healthy human donors. Virus Research, 1995, 36, 215-231.	1.1	9
189	Virus???host interactions in paediatric HIV-1 infection. Current Opinion in HIV and AIDS, 2007, 2, 399-404.	1.5	9
190	Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children. Clinical Drug Investigation, 2007, 27, 509-531.	1.1	9
191	Telomere and Telomerase in Carcinogenesis: Their Role as Prognostic Biomarkers. Current Pathobiology Reports, 2015, 3, 315-328.	1.6	9
192	Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child. Aids, 2000, 14, 1284.	1.0	9
193	Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus. PLoS ONE, 2017, 12, e0185128.	1.1	9
194	Size of HIVâ€1 reservoir is associated with telomere shortening and immunosenescence in earlyâ€treated European children with perinatally acquired HIVâ€1. Journal of the International AIDS Society, 2021, 24, e25847.	1.2	9
195	Virological and immunological response to antiretroviral therapy in HIV-1 infected children: genotypic and phenotypic assays in monitoring virological failure. New Microbiologica, 2004, 27, 45-50.	0.1	9
196	Structural Studies on Synthetic Peptides from the Principal Neutralizing Domain of HIV-1 gp120 That Bind to CD4 and Enhance HIV-1 Infection. Biochemical and Biophysical Research Communications, 1993, 191, 364-370.	1.0	8
197	CCR5, Vertical Transmission of HIV-1, and Disease Progression. Journal of Acquired Immune Deficiency Syndromes, 1999, 20, 211-212.	0.3	8
198	Italian consensus statement on paediatric HIV infection. Infection, 2010, 38, 301-319.	2.3	8

#	Article	IF	Citations
199	Differences in telomere length between sporadic and familial cutaneous melanoma. British Journal of Dermatology, 2016, 175, 937-943.	1.4	8
200	Predictive and prognostic significance of telomerase levels/telomere length in tissues and peripheral blood in head and neck squamous cell carcinoma. Scientific Reports, 2019, 9, 17572.	1.6	8
201	Anti-Proliferative and Pro-Apoptotic Effects of Short-Term Inhibition of Telomerase In Vivo and in Human Malignant B Cells Xenografted in Zebrafish. Cancers, 2020, 12, 2052.	1.7	8
202	Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort). Journal of the International AIDS Society, 2021, 24, e25717.	1.2	8
203	TERT Promoter Mutations and rs2853669 Polymorphism: Useful Markers for Clinical Outcome Stratification of Patients With Oral Cavity Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 782658.	1.3	8
204	Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica, 2006, 91, 244-7.	1.7	8
205	Resistance to Moloney Murine Sarcoma Virus (M-MuSV) Tumor Induction is Associated with Natural Antibody Production to Â«EndogenousÂ» Moloney Leukemia Virus (M-MuLV) in Balb/Mo Mice. Tumori, 1981, 67, 511-520.	0.6	7
206	Intrathecal Synthesis of Anti-HIV Oligoclonal IgG in HIV-Seropositive Patients Having No Signs of HIV-Induced Neurologic Diseases. Annals of the New York Academy of Sciences, 1988, 540, 615-618.	1.8	7
207	Analysis of Epsteinâ€“Barr virus (EBV) type and variant in spontaneous lymphoblastoid cells and Hu-SCID mouse tumours. Molecular and Cellular Probes, 1996, 10, 453-461.	0.9	7
208	Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells. Oncogene, 2003, 22, 906-918.	2.6	7
209	Relationship between moloney MSV tumor resistance and endogenous virogene expression in AKR mouse strain and its hybrids. International Journal of Cancer, 1978, 21, 179-185.	2.3	6
210	Tolerance to viral antigens in Mov-13 mice carrying endogenized moloney-murine leukemia virus. Cellular Immunology, 1984, 83, 379-388.	1.4	6
211	Adult T-Cell Leukemia (ATL): Clinical, Pathological and Virological Findings in Two Cases with Unusual Features. Leukemia and Lymphoma, 1992, 6, 261-266.	0.6	6
212	9-year-old child with falling CD4 count after neonatal HIV. Lancet, The, 1995, 346, 963.	6.3	6
213	Biological and conformational studies on analogues of a synthetic peptide enhancing HIV-1 infection. , 1998, 4, 436-448.		6
214	Telomerase Activity and Clinical Progression in Chronic Lymphoproliferative Disorders of B-Cell Lineage. Leukemia and Lymphoma, 2001, 41, 35-45.	0.6	6
215	Levels and patterns of HIV RNA viral load in untreated pregnant women. International Journal of Infectious Diseases, 2009, 13, 266-273.	1.5	6
216	Virus-specific T cell response prevents lymphoma development in mice infected by intrathymic inoculation of Moloney leukaemia virus (M-MuLV). Immunology, 1984, 51, 9-16.	2.0	6

#	Article	IF	Citations
217	A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial. Antiviral Therapy, 2006, 11, 857-67.	0.6	6
218	Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy. Frontiers in Immunology, 2022, 13, 860418.	2.2	6
219	How frequent and how early does the neurological involvement in HIV-positive children occur?. Child's Nervous System, 1990, 6, 406-408.	0.6	5
220	HIV antibodies in babies.. BMJ: British Medical Journal, 1992, 305, 367-367.	2.4	5
221	Improvements in virological control among women conceiving on combination antiretroviral therapy in Western Europe. Aids, 2013, 27, 2312-2315.	1.0	5
222	Host factors and early treatments to restrict paediatric HIV infection and early disease progression. Journal of Virus Eradication, 2015, 1, 140-147.	0.3	5
223	Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation â€“ a multicenter cohort study. Transplant International, 2021, 34, 743-753.	0.8	5
224	Relationship between changes in thymic emigrants and cell-associated HIV-1 DNA in HIV-1-infected children initiating antiretroviral therapy. Antiviral Therapy, 2005, 10, 63-71.	0.6	5
225	Mother-to-child HIV-1 transmission: Quantitative assessment of viral burden as a diagnostic tool and prognostic parameter in HIV-1-infected children. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 25-28.	0.7	4
226	Modifications of HIV-1 DNA and Provirus-Infected Cells During 24 Months of Intermittent Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 68-71.	0.9	4
227	Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications. Infectious Agents and Cancer, 2018, 13, 14.	1.2	4
228	Genetics of murine sarcoma virus (msv)â€"induced tumors in akr mice: Evidence that late progressing and early regressing tumors are controlled by different genes. International Journal of Cancer, 1977, 19, 565-575.	2.3	3
229	Lack of M-MuSV tumour regression associated with T lymphocyte tolerance. Nature, 1980, 285, 667-668.	13.7	3
230	Role of Infectious Virus Expression and Immune Response in Retrovirus-Induced Oncogenesis. Tumori, 1984, 70, 1-8.	0.6	3
231	Cordycepin reduces the sensitivity of BALB/Mo mouse lymphocytes to the induction of sister chromatid exchanges. Carcinogenesis, 1985, 6, 131-134.	1.3	3
232	HIV MONITORING OF PREGNANT WOMEN. Lancet, The, 1988, 331, 713-714.	6.3	3
233	Pediatric HIV-1 Infection: Advances and Perspectives in Diagnosis and Prognosis. Antibiotics and Chemotherapy, 1994, 46, 5-17.	0.5	3
234	Design, synthesis and CD4 binding studies of a fluorescent analogue of a peptide that enhances HIVâ€1 infectivity. Chemical Biology and Drug Design, 1998, 51, 110-115.	1.2	3

#	Article	IF	Citations
235	Dried blood spot sampling for detection of monoclonal immunoglobulin gene rearrangement. Leukemia Research, 2013, 37, 1265-1270.	0.4	3
236	Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection. Frontiers in Immunology, 2021, 12, 643189.	2.2	3
237	Primary HIV infection in infants: impact of highly active antiretroviral therapy on the natural course. Journal of Biological Regulators and Homeostatic Agents, 2002, 16, 53-7.	0.7	3
238	Characterization of Dualtropic Type C Retroviruses Isolated from Spontaneous Non-T Lymphomas of SJL/J(v+) MICE. Tumori, 1982, 68, 95-104.	0.6	2
239	Diffusion of HIV-1 virus into non-habitual categories at risk in European countries. European Journal of Cancer & Clinical Oncology, 1988, 24, 1677-1679.	0.9	2
240	CCR5 N-terminus peptides enhance X4 HIV-1 infection by CXCR4 up-regulation. Biochemical and Biophysical Research Communications, 2003, 307, 640-646.	1.0	2
241	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	6.0	2
242	Longâ€term clinical, virological and immunological outcomes following planned treatment interruption in HIVâ€infected children. HIV Medicine, 2021, 22, 172-184.	1.0	2
243	One Year Follow-Up Study of T-Cell Subsets and Incidence of Seropositivity for HTLV-I and HTLV-III Antibodies in Patients Treated â€œOn Demandâ€•or Sporadically with Clotting Concentrates. Thrombosis and Haemostasis, 1985, 54, 665-668.	1.8	2
244	The Prevalence of HTLV-III and HTLV-I Antibodies in Serum of Hemophiliacs. Thrombosis and Haemostasis, 1985, 54, 897-897.	1.8	2
245	Host factors and early treatments to restrict paediatric HIV infection and early disease progression. Journal of Virus Eradication, 2015, 1, 140-7.	0.3	2
246	Report from the First EPIICAL (Early-treated Perinatally HIV-infected Individuals: Improving Children's) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Rome, Italy. Journal of Virus Eradication, 2018, 4, 51-54.	0.3	2
247	Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children. Frontiers in Immunology, 2022, 13, 875692.	2.2	2
248	Assessing the Variability of Cell-Associated HIV DNA Quantification through a Multicenter Collaborative Study. Microbiology Spectrum, 2022, 10, .	1.2	2
249	Short- and Long-term Studies on Chemical Carcinogenesis in BALB/Mo Mice. Toxicologic Pathology, 1984, 12, 361-368.	0.9	1
250	Prevalence of HIV infection in a cohort of patients with congenital coagulation defects of the prothrombin complex factors. Blood Coagulation and Fibrinolysis, 1991, 2, 663-668.	0.5	1
251	Polymorphims of innate immunity genes influence disease progression in HIV-1 infected children. Retrovirology, 2012, 9, .	0.9	1
252	Immunological Findings in the CSF of HIV-1 Infected Patients. , 1990, , 13-22.		1

#	Article	IF	Citations
253	Plasma levels of total RNA and hTERT mRNA as biomarkers of response in rectal cancer patients receiving preoperative chemoradiotherapy.. Journal of Clinical Oncology, 2010, 28, 3648-3648.	0.8	1
254	Biological Predictors of De Novo Tumors in Solid Organ Transplanted Patients During Oncological Surveillance: Potential Role of Circulating TERT mRNA. Frontiers in Oncology, 2021, 11, 772348.	1.3	1
255	Maternal Antibody Epitope Mapping in Mother-to-Child Transmission of HIV. Advances in Experimental Medicine and Biology, 1991, 303, 47-52.	0.8	1
256	Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients. Frontiers in Oncology, 0, 12, .	1.3	1
257	Intrathecal synthesis of anti-HIV oligoclonal IgG in aids and ARC patients having not signs of HIV-related encephalopathy. Journal of Neuroimmunology, 1987, 16, 59-60.	1.1	0
258	No evidence of HIV-2 infection in subjects at risk for aids living in North-East Italy. European Journal of Epidemiology, 1991, 7, 682-685.	2.5	0
259	Intrafamilial transmission of HIV-1. Aids, 2003, 17, 2673-2674.	1.0	0
260	Response to Segat et al. â€˜Are DEFB1 gene polymorphisms associated with HIV-1 infection and virus replication?â€™. Aids, 2009, 23, 649-650.	1.0	0
261	Relationship between dynamics of Epsteinâ€Barr virus and immune activation in HIVâ€1 infected subjects in the HAART era. Journal of the International AIDS Society, 2010, 13, P213.	1.2	0
262	Reply to Zhang, Poznansky, and Crumpacker. Journal of Infectious Diseases, 2012, 206, 618-618.	1.9	0
263	936 The Interplay Between Telomerase and Epstein Barr Virus (EBV) â€“Silencing of HTERT Induces the EBV Lytic Cycle. European Journal of Cancer, 2012, 48, S225.	1.3	0
264	mTOR Inhibitors Maintain Low Levels of Immune Activation, Immune Senescence and EBV Load in Kidney Transplant Patients. Transplantation, 2018, 102, S201.	0.5	0
265	Faster Initial Viral Decay in Female Children Living With HIV. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 674-676.	0.6	0
266	Pediatric HIV/AIDS. , 2014, , 3467-3472.		0
267	Pediatric HIV/AIDS. , 2014, , 1-7.		0
268	Telomerase as Biomarker in Colorectal Cancer. , 2014, , 1-19.		0
269	Are children who clear HIV truly uninfected?. Nursing Standard (Royal College of Nursing (Great) Tj ETQq1 1 0.784314 rgBT /Overlock	0.1	0
270	Telomerase as Biomarker in Colorectal Cancer. Biomarkers in Disease, 2015, , 659-683.	0.0	0

#	Article	IF	Citations
271	Morphological and phenotypical changes in EBV positive lymphoblastoid cells infected by HIV-1. Leukemia, 1992, 6 Suppl 3, 38S-40S.	3.3	0
272	Viral determinants in HIV-1 transmission. Journal of Biological Regulators and Homeostatic Agents, 1997, 11, 32-6.	0.7	0